CSL

0.25%

$307.16 csl limited

Ann: Appendix 4D and Half Year Accounts, page-23

First 23 Last

Share
Profile

Follow
zaidi675

407 Posts.

21

14/02/19

00:40

Post #: 37430456
Share

Originally posted by madamswer: ↑

"Hi Adam,
I wonder if you are able to suggest what will be a reasonable entry price for someone who never held CSL before? I still do not believe why I did not buy it when it nearly touched $100 an Year or two ago. While it may never go that down but is it a reasonable value below 170?"

As you might know, I am a mad keen fan of this company and consider it to be the best quality ASX-listed company, for a host of reasons.

But I would not buy CSL at the current price, despite it being a truly wonderful business.

The reason lies in the investing adage of:

"Quality is what you buy; Value is what you get."

And in CSL's case, you are buying quality in spades, but at the current valuation multiple of around 30 times [*], you aren't getting much value.

[*] It warrants mentioning that CSL's earnings a significantly understated given the company expenses all of its ~US$800m of R&D expenditure. And $800m is highly significant in the context of a Pre-Tax Profit figure of around US$2.5bn. It stands to reason that, if CSL capitalised, say, half of its R&D spend (which the majority of other companies in CSL's situation would do), the company's Pre-Tax Profit would rise by a full one-third and the ensuing P/E multiple would be closer to 23 times which, while not 30 times, is still not cheap.

There is precious little valuation buffer or margin of safety inherent in the current stock price.

In my experience, every 4 or 5 years some extraneous factor - could be a regulatory scare, a trial that disappoints, the A$ strengthening, weaker-than-expected guidance or a financial market crisis - which causes CSL's share price to fall dramatically to a level that makes it attractive enough to buy.

My Rule of Thumb, which has served me well with CSL, is that I add to my holdings in the stock every time the "raw" P/E multiple falls below 25 times (i.e., when the P/E multiple, adjusted for excess R&D expense, falls to 17x or 18x.

..

Expand

As always, sincere thanks for not only providing some guidance but the thought process behind the working of it.

CSL Price at posting: $186.09 Sentiment: None Disclosure: Not Held
2 Upvote

0 Great analysis

Reply

Top Stories

HVN

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

PYC

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

CYM

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

CCO

The Calmer Co’s Anthony Noble reflects on record breaking FY24

HLX

Helix investor makes partial takeover bid, proposing board changes

VYS

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

TBN

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

LLC

Lendlease sells off US east coast construction operations in latest global divestment push

There are more pages in this discussion • 11 more messages in this thread...

First 23 Last

Add CSL (ASX) to my watchlist

(20min delay)
Last $307.16		Change -0.770(0.25%)		Mkt cap ! $148.4B

Open	High	Low	Value	Volume
$309.31	$309.89	$305.94	$474.0M	1.557M

Buyers (Bids)

No.	Vol.	Price($)
1	500	$307.00

Sellers (Offers)

Price($)	Vol.	No.
$307.30	1568	3

View Market Depth

No.	Vol.	Price($)
1	2369	306.160
4	270	305.000
1	55	304.880
1	2	304.800
1	55	304.670

Price($)	Vol.	No.
308.000	28	1
308.160	58	1
308.340	35	1
308.450	101	2
308.500	100	1

Last trade - 16.10pm 30/08/2024 (20 minute delay)

CSL (ASX) Chart

Ann: Appendix 4D and Half Year Accounts, page-23

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

The Calmer Co’s Anthony Noble reflects on record breaking FY24

Helix investor makes partial takeover bid, proposing board changes

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

Lendlease sells off US east coast construction operations in latest global divestment push

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Appendix 4D and Half Year Accounts, page-23

Top Stories

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

Week 35 Wrap: HotCopper’s top watched; ‘iron ore winter’ has started; Oz inflation @ 3.5% MoM; Harris fracking flip

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore

The Calmer Co’s Anthony Noble reflects on record breaking FY24

Helix investor makes partial takeover bid, proposing board changes

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

Lendlease sells off US east coast construction operations in latest global divestment push

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News